drug · small molecule

INGREZZA SPRINKLE

updated 2mo ago

by $NBIX NEUROCRINE BIOSCIENCES INC🔗 ChEMBL

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for movement disorder and 1 investigational indication.

targets

Synaptic vesicular amine transporter

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

INGREZZA SPRINKLE

trade names

Ingrezza, Ingrezza sprinkle

generic

VALBENAZINE TOSYLATE

MOA

12.1 Mechanism of Action The mechanism of action of valbenazine for the treatment of tardive dyskinesia and chorea in patients with Huntington’s disease is unclear, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.

indication

1 INDICATIONS AND USAGE INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia [see Clinical Studies ( 14.1 )] . - chorea associated with Huntington’s disease [see Clinical Studies ( 14.2 )] . INGREZZA and INGREZZA SPRINKLE are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated for the treatment of adults with: - tardive dyskinesia. ( 1 ) - chorea associated with Huntington’s disease. ( 1 )

INGREZZA SPRINKLE

targets

all catalysts(0)

News(0)

comments(0)

Report a data issue

🐶 often sniffed alongside